Centessa Pharmaceuticals Plc Stock Price, News & Analysis

Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has announced its management team's participation in two upcoming investor conferences in June 2025:

• The Jefferies 2025 Global Healthcare Conference on June 4, with a fireside chat at 11:40 AM ET
• The Goldman Sachs 46th Annual Global Healthcare Conference on June 10, with a fireside chat at 9:20 AM ET

Live webcasts and archived recordings of both events will be accessible through the \"Events and Publications\" section on Centessa's investor relations website.

Centessa Pharmaceuticals (Nasdaq: CNTA) reported its Q4 and full-year 2024 financial results, highlighting progress in its orexin receptor 2 (OX2R) agonist pipeline. The company's lead candidate, ORX750, showed positive Phase 1 results with significant wakefulness increases in sleep-deprived volunteers and is advancing in Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia.

Financial highlights include:

• Cash position of $482.2M as of December 31, 2024, expected to fund operations into mid-2027
• Q4 2024 R&D expenses increased to $60.9M (vs $29.7M in Q4 2023)
• Full-year 2024 net loss of $235.8M (vs $151.1M in 2023)

The company is advancing two additional compounds: ORX142 in IND-enabling studies with clinical data expected in 2025, and ORX489, their most potent OX2R agonist to date, also in IND-enabling studies.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that data from their Phase 1 clinical trial of ORX750, a novel orexin receptor 2 (OX2R) agonist, will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego.

The presentation will focus on Phase 1 clinical data of ORX750 in acutely sleep-deprived healthy participants. ORX750 is being developed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). The drug is currently being evaluated in an ongoing Phase 2a clinical trial called CRYSTAL-1.

The poster presentation will be delivered by Dr. Deborah Hartman, Global Scientific Head of the Orexin Program, on April 5, 2025, at 11:45 AM PT.

Centessa Pharmaceuticals (Nasdaq: CNTA) has announced its management team's participation in four upcoming investor conferences in early 2025. The schedule includes:

• Guggenheim SMID Cap Biotech Conference on February 6, 2025 (Fireside Chat at 1:00 PM ET)
• Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (Fireside Chat at 10:40 AM ET)
• TD Cowen 45th Annual Health Care Conference on March 4, 2025 (Fireside Chat at 1:50 PM ET)
• Leerink Partners Global Healthcare Conference on March 11, 2025 (Fireside Chat at 10:00 AM ET)

Live webcasts and archived recordings of these events will be accessible through the "Events and Publications" tab on Centessa's investor relations website.

Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed Stephen Kanes, MD PhD, as Chief Medical Officer. Dr. Kanes, a neuropsychiatrist with over 30 years of experience in neuroscience, clinical psychiatry, and drug development, joins the company as it advances its orexin receptor 2 (OX2R) agonist portfolio.

Dr. Kanes previously served as CMO at Sage Therapeutics (2013-2021), where he led the development of ZULRESSO®, the first approved treatment for Postpartum Depression. He was most recently CEO of EmbarkNeuro and previously held positions at AstraZeneca and the University of Pennsylvania. The appointment comes as Centessa progresses Phase 2a clinical studies of ORX750, targeting sleep-wake, neurological, neurodegenerative and psychiatric disorders.

Centessa Pharmaceuticals (CNTA) reported Q3 2024 financial results and announced positive interim data from its Phase 1 study of ORX750, showing significant increased wakefulness in sleep-deprived volunteers. The company initiated a Phase 2a study for narcolepsy and hypersomnia treatments, with data expected in 2025. Financial highlights include $518.4M in cash and equivalents, R&D expenses of $33.9M, and a net loss of $42.6M. Centessa discontinued SerpinPC development, reallocating approximately $200M savings to expand their OX2R agonist franchise. The company's cash runway extends into mid-2027.

Centessa Pharmaceuticals (Nasdaq: CNTA) has announced its management team's participation in three upcoming investor conferences. The company will attend the Guggenheim Healthcare Innovation Conference in Boston on November 13, 2024, with a fireside chat at 9:00 AM ET, the Jefferies London Healthcare Conference on November 19, 2024, at 1:30 PM GMT, and the 7th Annual Evercore HealthCONx Conference in Miami on December 5, 2024, at 10:00 AM ET. Live webcasts and recordings will be accessible through the company's investor relations website.

Centessa Pharmaceuticals (Nasdaq: CNTA) presented preclinical data for ORX142, a novel orexin receptor 2 (OX2R) agonist, at the 27th Congress of the European Sleep Research Society. The data from non-human primate (NHP) studies support ORX142 as a potential treatment for excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders.

Key findings include:

• ORX142 showed significant activity in promoting wakefulness at very low doses (0.03 mg/kg)
• It potently activated human OX2R with an EC50 of 0.069 nM and >13,000-fold selectivity over human OX1R
• Induced sustained increases in wakefulness, suppressing NREM and REM sleep
• Associated with normal physiological arousal and EEG power spectra signatures of enhanced alertness

ORX142 is currently in IND-enabling studies as Centessa's second OX2R agonist drug candidate.